A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
Status:
Terminated
Trial end date:
2019-11-15
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose, four-period, four sequential, and crossover study
conducted to assess the relative bioavailability of GSK3640254 mesylate tablets and
GSK3640254 mesylate capsules (in the presence of a moderate fat meal). This study will also
evaluate the effect of food (fasted, moderate fat meal, and high fat meal) on the
pharmacokinetics of GSK3640254 mesylate tablet formulation. Participants will be randomized
to receive a single dose of GSK3640254 200 milligram (mg) capsules under moderate fat
conditions and GSK3640254 200 mg tablets under moderate fat, fasted and high fat conditions
in each treatment period. Approximately 16 participants will be enrolled and the duration of
the study will be approximately 54 days.